Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Tomato who wrote (6292)	5/12/2002 3:16:42 PM
From: teevee	Respond to of 52153

Tomato, As an older, value investor, Biotech stocks all look expensive to me. So far, I am in the "green" with my first and only biotech investment, ISA (Isotechnika). It is holding up very well since the partnering deal with Roche and has yet to catch the "Biotech Blues", in spite of how the biotech multiples and "blue sky" valuations are shrinking. This might be due to the fact that ISA has not yet been discovered by Americans and has never traded at any near the kind of valuations that most US biotechs trade for. isotechnika.com cheers, teevee